Regorafenib in metastatic colorectal cancer: more data for clinical decisions
Regorafenib is a multiple kinase inhibitor. It influences/blocks angiogenesis (VEGFR1-3, TIE2), proliferation (KIT, RET, RAF-1, BRAF), metastatic activity (VEGFR2-3, PDGFR), tumor immunogenicity (CSF1R), tumor microenvironment (PDGFR-, PDGFR-, FGFR1-2). Regorafenib has several indications including...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | RU |
| Publié: |
IP Habib O.N.
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/d60c0e70abad4938848b0986a5a6d701 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|